Neuraminidase Inhibitor Susceptibility of Influenza Viruses Circulating in Bulgaria during the Last Four Consecutive Epidemic Seasons (2011/12 to 2014/15)
Keywords:
Influenza virus, Resistance, H275Y mutationAbstract
Emergence of resistant influenza virus progeny to currently approved antiviral drugs determines the need for antiviral susceptibility monitoring. The aim of the present study is to analyze neuraminidase inhibitor susceptibility of influenza viruses circulating in Bulgaria during the 2011/2012, 2012/2013, 2013/2014 and 2014/2015 flu seasons. A phenotypic fluorescence-based assay with MUNANA substrate was conducted with 93 influenza A(H1N1)pdm09, A(H3N2) and type B isolates. Screening of 352 influenza A(H1N1)pdm09 viruses was carried out using a Real Time RT-PCR discrimination assay for detection of the H275Y oseltamivir resistance point mutation. Phenotypic (IC50) evidence for resistance or reduced susceptibility to neuraminidase inhibitors was not found for any of the influenza A(H1N1)pdm09, A(H3N2) and type B viruses screened. Only one (0,3%) influenza A(H1N1)pdm09 virus carrying the H275Y substitution was detected. Real Time RT-PCR assay could be applied to screen large numbers of clinical A(H1N1)pdm09 influenza virus positive samples for oseltamivir resistance. The present study highlights the importance of continued influenza antiviral susceptibility monitoring in clinical specimens.
References
[1] WHO. Influenza (seasonal). Available: http://www.who.int/mediacentre/factsheets/fs211/en/.
[2] Nguyen HT, Fry AM, Gubareva LV. “Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods”. Antivir Ther; 17(1 Pt B), 2012, pp. 159-73.
[3] Samson M, Pizzorno A, Abed Y, Boivin G. “Influenza virus resistance to neuraminidase inhibitors”.Antiviral Res, 98(2), pp 174-85, 2013.
[4] WHO. “An overview of amino acid substitutions in influenza neuraminidase associated with resistance or reduced susceptibility to NAIs”. Available: http://who.int/influenza/gisrs_laboratory/ antiviral_susceptibility/nai_overview/en/.
[5] Renaud C, Kuypers J, Englund JA. ”Emerging oseltamivir resistance in seasonal and pandemic influenza A/H1N1”. J Clin Virol, 52(2), pp70-8, 2011.
[6] Pozo F, Lina B, Andrade HR, Enouf V, Kossyvakis A, Broberg E, Daniels R, Lackenby A, Meijer A. ”Community Network of Reference Laboratories for Human Influenza in Europe.Guidance for clinical and public health laboratories testing for influenza virus antiviral drug susceptibility in Europé”. J Clin Virol, 57(1), pp 5-12, 2013.
[7] Van der Vries E, Jonges M, Herfst S, Maaskant J, Van der Linden A, Guldemeester J, Aron GI, Bestebroer TM, Koopmans M, Meijer A, Fouchier RA, Osterhaus AD, Boucher CA, Schutten M. “Evaluation of a rapid molecular algorithm for detection of pandemic influenza A(H1N1) 2009 virus and screening for a key oseltamivir resistance (H275Y) substitution in neuraminidase”. J Clin Virol., 47(1), pp 34-7, 2010.
[8] Hindiyeh M, Ram D, Mandelboim M, Meningher T, Hirsh S, Robinov J, Levy V, Orzitzer S, Azar R, Grossman Z, Mendelson E. “Rapid detection of influenza A pandemic (H1N1) 2009 virus neuraminidase resistance mutation H275Y by real-time reverse transcriptase PCR”. J Clin Microbiol, 48(5), pp1884-7, 2010.
[9] Suzuki Y, Saito R, Sato I, Zaraket H, Nishikawa M, Tamura T, Dapat C, Caperig-Dapat I, Baranovich T, Suzuki T, Suzuki H. “Identification of oseltamivir resistance among pandemic and seasonal influenza A (H1N1) viruses by an His275Tyr genotyping assay using the cycling probe method”. J Clin Microbiol, 49(1), pp 125-30, 2011.
[10] Shu B, Wu KH, Emery S, Villanueva J, Johnson R, Guthrie E, Berman L, Warnes C, Barnes N, Klimov A, Lindstrom S. “Design and performance of the CDC real-time reverse transcriptase PCR swine flu panel for detection of 2009 A (H1N1) pandemic influenza virus”. J Clin Microbiol, 49(7), pp 2614-9, 2011.
[11] WHO. “Global Influenza Surveillance Network. Manual for the laboratory diagnosis and virological surveillance of influenza. WHO Press, Geneva, Switzerland”. Available: http://whqlibdoc .who.int/publications/2011/9789241548090_eng.pdf
[12] Meetings of the WHO working group on surveillance of influenza antiviral susceptibility – Geneva, November 2011 and June 2012. Weekly Epidemiol Rec, 87(39), pp 369–380, 2012.
[13] Ikematsu H, Kawai N, Iwaki N, Kashiwagi S. “In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of influenza virus in the Japanese 2012-2013 season”. J Infect Chemother; 21(1), pp 39-42, 2015.
[14] Duwe SC, Wedde M, Birkner P, Schweiger B. “Genotypic and phenotypic resistance of pandemic A/H1N1 influenza viruses circulating in Germany”. Antiviral Res, 89, pp 115–118, 2011.
[15] Longtin J, Patel S, Eshaghi A, Lombos E, Higgins R, Alexander D, Olsha R, Doyle J, Tran D, Sarabia A, Lee C, Bastien N, Li Y, Low D, Boivin G, Gubbay J. “Neuraminidase-inhibitor resistance testing for pandemic influenza A(H1N1) 2009 in Ontario, Canada”. J Clin Virol, 50(3), pp 257-61, 2011.
[16] Hurt AC. “The epidemiology and spread of drug resistant human influenza viruses”. Curr Opin Virol, Vol 8, pp 22-9, 2014.
[17] Meijer A, Rebelo-de-Andrade H, Correia V, Besselaar T, Drager-Dayal R, Fry A, Gregory V, Gubareva L, Kageyama T, Lackenby A, Lo J, Odagiri T, Pereyaslov D, Siqueira MM, Takashita E, Tashiro M, Wang D, Wong S, Zhang W, Daniels RS, Hurt AC. “Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012-2013”. Antiviral Res, Vol 110, pp 31-41, 2014.
[18] Takashita E, Meijer A, Lackenby A, Gubareva L, Rebelo-de-Andrade H, Besselaar T, Fry A, Gregory V, Leang SK, Huang W, Lo J, Pereyaslov D, Siqueira MM, Wang D, Mak GC, Zhang W, Daniels RS, Hurt AC, Tashiro M. “Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014”. Antiviral Res, Vol 117, pp 27-38, 2015.
[19] Dapat C, Kondo H, Dapat IC, Baranovich T, Suzuki Y, Shobugawa Y, Saito K, Saito R, Suzuki H. “Neuraminidase Inhibitor Susceptibility Profile of Pandemic and Seasonal Influenza Viruses during the 2009-2010 and 2010-2011 Influenza Seasons in Japan”. Antiviral Res, 99(3) pp261-269, 2013.
[2] Nguyen HT, Fry AM, Gubareva LV. “Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods”. Antivir Ther; 17(1 Pt B), 2012, pp. 159-73.
[3] Samson M, Pizzorno A, Abed Y, Boivin G. “Influenza virus resistance to neuraminidase inhibitors”.Antiviral Res, 98(2), pp 174-85, 2013.
[4] WHO. “An overview of amino acid substitutions in influenza neuraminidase associated with resistance or reduced susceptibility to NAIs”. Available: http://who.int/influenza/gisrs_laboratory/ antiviral_susceptibility/nai_overview/en/.
[5] Renaud C, Kuypers J, Englund JA. ”Emerging oseltamivir resistance in seasonal and pandemic influenza A/H1N1”. J Clin Virol, 52(2), pp70-8, 2011.
[6] Pozo F, Lina B, Andrade HR, Enouf V, Kossyvakis A, Broberg E, Daniels R, Lackenby A, Meijer A. ”Community Network of Reference Laboratories for Human Influenza in Europe.Guidance for clinical and public health laboratories testing for influenza virus antiviral drug susceptibility in Europé”. J Clin Virol, 57(1), pp 5-12, 2013.
[7] Van der Vries E, Jonges M, Herfst S, Maaskant J, Van der Linden A, Guldemeester J, Aron GI, Bestebroer TM, Koopmans M, Meijer A, Fouchier RA, Osterhaus AD, Boucher CA, Schutten M. “Evaluation of a rapid molecular algorithm for detection of pandemic influenza A(H1N1) 2009 virus and screening for a key oseltamivir resistance (H275Y) substitution in neuraminidase”. J Clin Virol., 47(1), pp 34-7, 2010.
[8] Hindiyeh M, Ram D, Mandelboim M, Meningher T, Hirsh S, Robinov J, Levy V, Orzitzer S, Azar R, Grossman Z, Mendelson E. “Rapid detection of influenza A pandemic (H1N1) 2009 virus neuraminidase resistance mutation H275Y by real-time reverse transcriptase PCR”. J Clin Microbiol, 48(5), pp1884-7, 2010.
[9] Suzuki Y, Saito R, Sato I, Zaraket H, Nishikawa M, Tamura T, Dapat C, Caperig-Dapat I, Baranovich T, Suzuki T, Suzuki H. “Identification of oseltamivir resistance among pandemic and seasonal influenza A (H1N1) viruses by an His275Tyr genotyping assay using the cycling probe method”. J Clin Microbiol, 49(1), pp 125-30, 2011.
[10] Shu B, Wu KH, Emery S, Villanueva J, Johnson R, Guthrie E, Berman L, Warnes C, Barnes N, Klimov A, Lindstrom S. “Design and performance of the CDC real-time reverse transcriptase PCR swine flu panel for detection of 2009 A (H1N1) pandemic influenza virus”. J Clin Microbiol, 49(7), pp 2614-9, 2011.
[11] WHO. “Global Influenza Surveillance Network. Manual for the laboratory diagnosis and virological surveillance of influenza. WHO Press, Geneva, Switzerland”. Available: http://whqlibdoc .who.int/publications/2011/9789241548090_eng.pdf
[12] Meetings of the WHO working group on surveillance of influenza antiviral susceptibility – Geneva, November 2011 and June 2012. Weekly Epidemiol Rec, 87(39), pp 369–380, 2012.
[13] Ikematsu H, Kawai N, Iwaki N, Kashiwagi S. “In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of influenza virus in the Japanese 2012-2013 season”. J Infect Chemother; 21(1), pp 39-42, 2015.
[14] Duwe SC, Wedde M, Birkner P, Schweiger B. “Genotypic and phenotypic resistance of pandemic A/H1N1 influenza viruses circulating in Germany”. Antiviral Res, 89, pp 115–118, 2011.
[15] Longtin J, Patel S, Eshaghi A, Lombos E, Higgins R, Alexander D, Olsha R, Doyle J, Tran D, Sarabia A, Lee C, Bastien N, Li Y, Low D, Boivin G, Gubbay J. “Neuraminidase-inhibitor resistance testing for pandemic influenza A(H1N1) 2009 in Ontario, Canada”. J Clin Virol, 50(3), pp 257-61, 2011.
[16] Hurt AC. “The epidemiology and spread of drug resistant human influenza viruses”. Curr Opin Virol, Vol 8, pp 22-9, 2014.
[17] Meijer A, Rebelo-de-Andrade H, Correia V, Besselaar T, Drager-Dayal R, Fry A, Gregory V, Gubareva L, Kageyama T, Lackenby A, Lo J, Odagiri T, Pereyaslov D, Siqueira MM, Takashita E, Tashiro M, Wang D, Wong S, Zhang W, Daniels RS, Hurt AC. “Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012-2013”. Antiviral Res, Vol 110, pp 31-41, 2014.
[18] Takashita E, Meijer A, Lackenby A, Gubareva L, Rebelo-de-Andrade H, Besselaar T, Fry A, Gregory V, Leang SK, Huang W, Lo J, Pereyaslov D, Siqueira MM, Wang D, Mak GC, Zhang W, Daniels RS, Hurt AC, Tashiro M. “Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014”. Antiviral Res, Vol 117, pp 27-38, 2015.
[19] Dapat C, Kondo H, Dapat IC, Baranovich T, Suzuki Y, Shobugawa Y, Saito K, Saito R, Suzuki H. “Neuraminidase Inhibitor Susceptibility Profile of Pandemic and Seasonal Influenza Viruses during the 2009-2010 and 2010-2011 Influenza Seasons in Japan”. Antiviral Res, 99(3) pp261-269, 2013.
Downloads
Published
2015-05-22
How to Cite
Angelova, S. G., Georgieva, I. L., Teodosieva, A. A., & Korsun, N. S. (2015). Neuraminidase Inhibitor Susceptibility of Influenza Viruses Circulating in Bulgaria during the Last Four Consecutive Epidemic Seasons (2011/12 to 2014/15). American Scientific Research Journal for Engineering, Technology, and Sciences, 12(1), 162–169. Retrieved from https://asrjetsjournal.org/index.php/American_Scientific_Journal/article/view/748
Issue
Section
Articles
License
Authors who submit papers with this journal agree to the following terms.
